<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467024</url>
  </required_header>
  <id_info>
    <org_study_id>MP-EIA-HTLV-001B</org_study_id>
    <nct_id>NCT01467024</nct_id>
  </id_info>
  <brief_title>Evaluation of the MP Diagnostics HTLV Blot 2.4</brief_title>
  <official_title>Evaluation of the MP Diagnostics HTLV Blot 2.4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MP Biomedicals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vital Systems Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MP Biomedicals, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:&#xD;
&#xD;
        1. To assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4.&#xD;
&#xD;
        2. To conduct a sensitivity analysis of the HTLV Blot 2.4 using a known positive&#xD;
           population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective study designed to assess the validity and reproducibility of the MP&#xD;
      Diagnostics IVD device, the HTLV Blot 2.4 (MP Blot), in various populations. The study will&#xD;
      be conducted at three geographical distinct locations.&#xD;
&#xD;
      The validity of the MP Blot will be assessed by calculating the following:&#xD;
&#xD;
        1. Percent negative agreement with CDPHL Algorithm on 200 EIA negative specimens&#xD;
&#xD;
        2. Percent positive agreement with CDPHL Algorithm on 200 EIA repeat reactive specimens&#xD;
&#xD;
      The sensitivity of the MP Blot will be evaluated by testing 200 known positive specimens. The&#xD;
      study will be performed using three product lots at three clinical sites.&#xD;
&#xD;
      The reproducibility of the MP Blot will be assessed by testing two replicates of a three&#xD;
      member panel at three clinical testing sites with each of three lots of product over multiple&#xD;
      days by three operators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>HTLV-I Infections</condition>
  <condition>HTLV-II Infections</condition>
  <condition>Human T-lymphotropic Virus 1</condition>
  <condition>Human T-lymphotropic Virus 2</condition>
  <condition>HTLV I Associated T Cell Leukemia Lymphoma</condition>
  <condition>HTLV I Associated Myelopathies</condition>
  <arm_group>
    <arm_group_label>EIA Negative</arm_group_label>
    <description>Blood donor specimens that tested non-reactive by previously licensed HTLV screening assay.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EIA Repeat Reactive</arm_group_label>
    <description>Blood donor specimens that tested repeat reactive by previously licensed HTLV screening assay, but are unconfirmed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Known Positive</arm_group_label>
    <description>Blood donor specimens that tested repeat reactive with a licensed HTLV screening assay and have been confirmed through additional, unlicensed supplemental testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CDPHL Algorithm</intervention_name>
    <description>Supplemental testing algorithm performed by the CDPHL.</description>
    <arm_group_label>EIA Negative</arm_group_label>
    <arm_group_label>EIA Repeat Reactive</arm_group_label>
    <arm_group_label>Known Positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All populations are from whole blood donors.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  EIA Negative Population&#xD;
&#xD;
               1. Male or female&#xD;
&#xD;
               2. Completion of a health history evaluation for routine donor screening&#xD;
&#xD;
               3. Willing and able to provide informed consent&#xD;
&#xD;
               4. Negative screening assay results for all ARC screening assays&#xD;
&#xD;
          -  EIA Repeat Reactive Population&#xD;
&#xD;
               1. Male or female&#xD;
&#xD;
               2. Completion of a health history evaluation for routine donor screening&#xD;
&#xD;
               3. Willing and able to provide informed consent&#xD;
&#xD;
               4. Previous RR result by bioMerieux ELISA, Abbott EIA, and / or Abbott ChLIA PRISM&#xD;
&#xD;
          -  Known Positive Population&#xD;
&#xD;
               1. Male or female&#xD;
&#xD;
               2. Willing and able to provide informed consent&#xD;
&#xD;
               3. Previous reactive screening test using either the bioMerieux ELISA, the Abbott&#xD;
                  EIA or the Abbott ChLIA PRISM, followed by supplemental testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  EIA Negative Population&#xD;
&#xD;
               1. Inadequate sample volume for testing&#xD;
&#xD;
               2. Unable to provide samples that meet the sample suitability requirements for&#xD;
                  testing&#xD;
&#xD;
               3. Positive screening result for any infectious disease tested by ARC&#xD;
&#xD;
          -  EIA Repeat Reactive Population&#xD;
&#xD;
               1. Inadequate sample volume for testing&#xD;
&#xD;
               2. Unable to provide samples that meet the sample suitability requirements for&#xD;
                  testing&#xD;
&#xD;
               3. Positive result for HIV, HBV, HCV, or any other infectious disease&#xD;
&#xD;
          -  Known Positive Population&#xD;
&#xD;
               1. Unwilling or unable to provide informed consent&#xD;
&#xD;
               2. Unable to provide adequate sample volume for testing&#xD;
&#xD;
               3. Unable to provide samples that meet the sample suitability requirements for&#xD;
                  testing&#xD;
&#xD;
               4. Positive result for HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Stramer, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>American National Red Cross</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Department of Public Health</name>
      <address>
        <city>Richmond</city>
        <state>California</state>
        <zip>94804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LABS, Inc</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>38611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>October 31, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HTLV</keyword>
  <keyword>Confirmatory</keyword>
  <keyword>Supplemental</keyword>
  <keyword>Blot</keyword>
  <keyword>HTLV-I</keyword>
  <keyword>HTLV-II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HTLV-I Infections</mesh_term>
    <mesh_term>Paraparesis, Tropical Spastic</mesh_term>
    <mesh_term>HTLV-II Infections</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Spinal Cord Diseases</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 26, 2017</submitted>
    <returned>August 3, 2017</returned>
    <submitted>September 27, 2017</submitted>
    <returned>July 19, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

